Related Experiment Video

Updated: May 6, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K

mTOR plays critical roles in pancreatic cancer stem cells through specific and stemness-related functions

Shyuichiro Matsubara1, Qiang Ding, Yumi Miyazaki

  • 1Cancer and Regenerative Medicine, Frontier Biomedical Science and Swine Research Center, Sakuragaoka, Kagoshima, 890-8520, Japan.

Scientific Reports
|November 16, 2013
PubMed

Insights

The mammalian target of rapamycin (mTOR) pathway is crucial for maintaining pancreatic cancer stem cells. Inhibiting mTOR with rapamycin reduced cancer stem cell viability and self-renewal, suggesting mTOR as a therapeutic target.

Area of Science:

  • Oncology
  • Cancer Stem Cell Biology
  • Molecular Targeted Therapy

Background:

  • Pancreatic cancer exhibits frequent KRAS mutations.
  • The mammalian target of rapamycin (mTOR) pathway, downstream of RAS, influences stem cell behavior.
  • The role of mTOR in pancreatic cancer stem cells requires further investigation.

Purpose of the Study:

  • To investigate the significance of the mTOR pathway in maintaining pancreatic cancer stem cell properties.
  • To determine if mTOR inhibition affects pancreatic cancer stem cell viability and self-renewal.
  • To compare the effects of mTOR inhibition with Hedgehog pathway inhibition in pancreatic cancer stem cells.

Main Methods:

  • Treatment of CD133(+) pancreatic cancer cells with the mTOR inhibitor rapamycin.
  • Assessment of cell viability and sphere formation (an indicator of self-renewal).
  • Comparison of rapamycin's effects with cyclopamine, a Hedgehog pathway inhibitor.

Main Results:

  • Rapamycin significantly reduced the viability of CD133(+) pancreatic cancer cells.
  • Rapamycin decreased sphere formation in CD133(+) cells, indicating reduced self-renewal.
  • The mTOR pathway demonstrated a distinct role in maintaining cancer stem cells compared to the Hedgehog pathway.

Conclusions:

  • The mTOR pathway plays a critical role in maintaining pancreatic cancer stem cells.
  • mTOR inhibition effectively reduces pancreatic cancer stem cell viability and self-renewal.
  • mTOR represents a promising therapeutic target for eliminating pancreatic cancer stem cells.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

959
Isolation of Stem Cells from Human Pancreatic Cancer Xenografts11:44

Isolation of Stem Cells from Human Pancreatic Cancer Xenografts

Published on: September 26, 2010

23.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

2.0K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.5K